| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
|
Circulation
|
2013
|
3.02
|
|
2
|
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
|
BMJ
|
2014
|
2.69
|
|
3
|
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.
|
Eur Heart J
|
2015
|
1.92
|
|
4
|
Novel HDL-directed pharmacotherapeutic strategies.
|
Nat Rev Cardiol
|
2011
|
1.91
|
|
5
|
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.
|
J Lipid Res
|
2012
|
1.46
|
|
6
|
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
|
N Engl J Med
|
2017
|
1.44
|
|
7
|
Residual macrovascular risk in 2013: what have we learned?
|
Cardiovasc Diabetol
|
2014
|
1.20
|
|
8
|
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.
|
J Lipid Res
|
2011
|
1.18
|
|
9
|
Rationale for cholesteryl ester transfer protein inhibition.
|
Curr Opin Lipidol
|
2012
|
1.15
|
|
10
|
Dysfunctional HDL and atherosclerotic cardiovascular disease.
|
Nat Rev Cardiol
|
2015
|
1.11
|
|
11
|
Lipids, blood pressure and kidney update 2015.
|
Lipids Health Dis
|
2015
|
1.00
|
|
12
|
Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
|
Eur Heart J
|
2012
|
0.95
|
|
13
|
Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.
|
Vasc Health Risk Manag
|
2014
|
0.92
|
|
14
|
Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
|
Clin Pharmacokinet
|
2013
|
0.89
|
|
15
|
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
|
J Lipid Res
|
2012
|
0.88
|
|
16
|
HDL, Atherosclerosis, and Emerging Therapies.
|
Cholesterol
|
2013
|
0.87
|
|
17
|
Mechanistic systems modeling to guide drug discovery and development.
|
Drug Discov Today
|
2012
|
0.86
|
|
18
|
HDL cholesterol is not HDL--don't judge the book by its cover.
|
Nat Rev Cardiol
|
2012
|
0.85
|
|
19
|
HDL and cognition in neurodegenerative disorders.
|
Neurobiol Dis
|
2014
|
0.84
|
|
20
|
Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.
|
Arterioscler Thromb Vasc Biol
|
2015
|
0.83
|
|
21
|
Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
|
Vasc Health Risk Manag
|
2012
|
0.82
|
|
22
|
High density lipoprotein and cardiovascular diseases.
|
World J Cardiol
|
2013
|
0.81
|
|
23
|
CETP inhibitors and cardiovascular disease: Time to think again.
|
F1000Res
|
2014
|
0.81
|
|
24
|
Hypertriglyceridemia and Cardiovascular Diseases: Revisited.
|
Korean Circ J
|
2016
|
0.80
|
|
25
|
Pharmacotherapies for lipid modification: beyond the statins.
|
Nat Rev Cardiol
|
2013
|
0.80
|
|
26
|
Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
|
Vasc Health Risk Manag
|
2012
|
0.78
|
|
27
|
New Era of Lipid-Lowering Drugs.
|
Pharmacol Rev
|
2016
|
0.77
|
|
28
|
Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
|
J Clin Lipidol
|
2014
|
0.77
|
|
29
|
CETP Inhibition: Past Failures and Future Hopes.
|
Clin Med Insights Cardiol
|
2016
|
0.76
|
|
30
|
Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk.
|
Hum Genet
|
2016
|
0.75
|
|
31
|
Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.
|
Blood Transfus
|
2015
|
0.75
|
|
32
|
Treatment of dyslipidemia.
|
F1000Prime Rep
|
2014
|
0.75
|
|
33
|
Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?
|
J Lipid Res
|
2015
|
0.75
|
|
34
|
Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.
|
Clin Lipidol
|
2013
|
0.75
|
|
35
|
Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects.
|
Drug Des Devel Ther
|
2016
|
0.75
|
|
36
|
Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis.
|
Am J Cardiol
|
2013
|
0.75
|
|
37
|
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.
|
Am Heart J
|
2017
|
0.75
|